文献速递产科母胎医学

产科急性重度高血压规范治疗的影响因素

Factors associated with appropriate treatment of acute-onset severe obstetrical hypertension.
PubMed 文献 · Am J Obstet Gynecol · 2021-05-20

该病例对照研究纳入2013至2020年单中心39918例分娩中1987例(5.0%)持续重度产科高血压患者,仅26.8%在60分钟内接受一线降压治疗,17.9%延迟治疗,55.3%未治疗。黑人、西班牙裔及<37周妊娠者更可能获规范治疗,夜间发作和产后阶段治疗可能性更低。

要点

  • 持续重度产科高血压中仅26.8%在60分钟内接受一线降压治疗。
  • 夜间发作(19:00至6:59)和产后阶段与未治疗风险升高相关。
  • 黑人、西班牙裔及<37周妊娠者更可能接受规范治疗。

核心结论

  • 约半数持续重度产科高血压患者未接受推荐的一线降压治疗。
  • 接受治疗者中约40%为延迟治疗。
  • 夜间发作和产后阶段与未接受一线降压治疗相关。

研究设计与样本

  • 单中心病例对照研究,纳入2013年10月1日至2020年8月31日分娩住院期间持续重度高血压的孕妇和产后患者。
  • 持续重度高血压定义为1小时内至少2次收缩压≥160 mm Hg或舒张压≥110 mm Hg。
  • 共39918例分娩,其中1987例(5.0%)合并持续重度产科高血压。

主要发现

  • 532例(26.8%)接受推荐治疗,356例(17.9%)延迟治疗,1099例(55.3%)未接受一线降压治疗。
  • 接受推荐治疗者更可能为黑人(aOR 1.85;95%CI 1.36-2.51)、西班牙裔(aOR 1.77;95%CI 1.28-2.52)或<37周妊娠(aOR 6.65;95%CI 5.08-8.72)。
  • 夜间发作(19:00至6:59)治疗可能性更低(aOR 0.79;95%CI 0.64-0.97),产后阶段治疗可能性更低(aOR 0.66;95%CI 0.51-0.86)。

关键数值与推荐

  • 推荐治疗定义为首次或第二次重度血压测量后60分钟内给予一线降压药(静脉拉贝洛尔、静脉肼屈嗪或即释口服硝苯地平)。
  • 延迟治疗定义为第二次血压升高后>60分钟给予一线药物。
  • 未治疗定义为从未给予一线药物。

临床怎么用

  • 对持续重度产科高血压患者应确保60分钟内给予一线降压治疗,尤其关注夜间和产后阶段。
  • 针对无社会人口学和临床危险因素的患者,也应提高规范治疗意识。
  • 实施基于ACOG最新指南的质量改进措施和机构政策可改善治疗率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The American College of Obstetricians and Gynecologists recommends that pregnant patients receive expeditious treatment with first-line antihypertensive agents within 1 hour of confirmed severe hypertension to reduce the risk for maternal stroke. However, it is unknown how often this guideline is followed and what factors influence a patient's likelihood of receiving guideline-concordant care. OBJECTIVE: We aimed to identify factors associated with receiving guideline-concordant treatment for an obstetrical hypertensive emergency. STUDY DESIGN: We present a case-control study of all pregnant and postpartum patients who had persistent severe hypertension (≥2 systolic blood pressures ≥160 mm Hg or diastolic blood pressure ≥110 mm Hg, or both within 1 hour of each other) during their delivery hospitalization at a tertiary hospital from October 1, 2013, to August 31, 2020. Data were extracted from the hospital electronic medical records using standard definitions and billing and diagnosis codes. We defined receipt of the recommended treatment as administration of a first-line antihypertensive agent (intravenous labetalol, intravenous hydralazine, or immediate-release oral nifedipine) within 60 minutes of the first or second severe-range blood pressure measurement during their delivery hospitalization. Delayed treatment was defined as the administration of a first-line agent >60 minutes after the second elevated blood pressure measurement. Patients were considered untreated if a first-line agent was never administered. Maternal sociodemographic, clinical and pregnancy factors, and time and day of the week of the hypertensive emergency were compared among patients who received the recommended treatment, those who received delayed treatment, and those who were untreated. Bivariate analyses were performed, and multinomial and multivariable logistic regression models were used to adjust for potential confounders. RESULTS: Of the 39,918 deliveries in the cohort, 1987 (5.0%) were complicated by severe, persistent obstetrical hypertension. Of these patients, 532 (26.8%) received the recommended treatment, 356 (17.9%) received delayed treatment, and 1099 (55.3%) did not receive any first-line antihypertensive therapy. The multinomial regression models that were used to compare these 3 groups indicated that patients who received the recommended treatment were more likely to be Black (adjusted odds ratio, 1.85; 95% confidence interval, 1.36-2.51), Hispanic (adjusted odds ratio, 1.77; 95% confidence interval, 1.28-2.52), or pregnant and at <37 weeks of gestation (adjusted odds ratio, 6.65; 95% confidence interval, 5.08-8.72). Treatment was less likely if the severe obstetrical hypertension emergency occurred overnight (7:00 PM to 6:59 AM) (adjusted odds ratio, 0.79; 95% confidence interval, 0.64-0.97) or during the postpartum period (adjusted odds ratio, 0.66; 95% confidence interval, 0.51-0.86). CONCLUSION: Approximately half of obstetrical patients with at least 2 documented severely elevated blood pressure measurements did not receive the recommended antihypertensive treatment. Of those who did receive treatment, about 40% had delayed treatment. Black and Hispanic race and preterm gestation were associated with an increased likelihood of receiving the recommended treatment when compared with White race and term pregnancies. Patients whose severe obstetrical hypertension emergency occurred overnight and those who were postpartum were less likely to receive any first-line antihypertensive treatment. Overall, patients without sociodemographic and clinical risk factors for severe obstetrical hypertension or other pregnancy complications were less likely to be treated. However, treatment improved significantly over time with the implementation of targeted quality measures and specific institutional policies based on the American College of Obstetricians and Gynecologists' latest severe obstetrical hypertension management guidelines.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Deshmukh US, Lundsberg LS, Culhane JF, et al. Factors associated with appropriate treatment of acute-onset severe obstetrical hypertension. Am J Obstet Gynecol. 2021. PMID: 34023314. doi:10.1016/j.ajog.2021.05.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。